Kwon Eun-Bin, Kim Young Soo, Kim Buyun, Kim Se-Gun, Na Sung-Joon, Go Younghoon, Choi Hong Min, Lee Hye Jin, Han Sang Mi, Choi Jang-Gi
Korean Medicine Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Republic of Korea.
Department of Agricultural Biology, National Institute of Agricultural Sciences, Rural Development Administration, Wanju 55365, Republic of Korea.
Antioxidants (Basel). 2023 Oct 30;12(11):1935. doi: 10.3390/antiox12111935.
Herpes simplex virus 1 (HSV-1) is double-stranded DNA virus that belongs to the Orthoherpesviridae family. It causes serious neurological diseases of the central nervous system, such as encephalitis. The current U.S. Food and Drug Administration (FDA)-approved drugs for preventing HSV-1 infection include acyclovir (ACV) and valacyclovir; however, their long-term use causes severe side effects and often results in the emergence of drug-resistant strains. Therefore, it is important to discover new antiviral agents that are safe and effective against HSV-1 infection. Korean chestnut honey (KCH) has various pharmacological activities, such as antioxidant, antibacterial, and anti-inflammation effects; however, antiviral effects against HSV-1 have not yet been reported. Therefore, we determined the antiviral activity and mechanism of action of KCH after HSV-1 infection on the cellular level. KCH inhibited the HSV-1 infection of host cells through binding and virucidal steps. KCH decreased the production of reactive oxygen species (ROS) and calcium (Ca) following HSV-1 infection and suppressed the production of inflammatory cytokines by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-кB) activity. Furthermore, we found that KCH inhibited the expression of the nod-like receptor protein 3 (NLRP3) inflammasome during HSV-1 infection. Taken together, the antiviral effects of KCH occur through multiple targets, including the inhibition of viral replication and the ROS-mediated NLRP3 inflammasome pathway. Our findings suggest that KCH has potential for the treatment of HSV-1 infection and related diseases.
单纯疱疹病毒1型(HSV-1)是一种双链DNA病毒,属于正疱疹病毒科。它会引发中枢神经系统的严重神经疾病,如脑炎。美国食品药品监督管理局(FDA)目前批准用于预防HSV-1感染的药物包括阿昔洛韦(ACV)和伐昔洛韦;然而,长期使用这些药物会导致严重的副作用,并且常常会导致耐药菌株的出现。因此,发现对HSV-1感染安全有效的新型抗病毒药物非常重要。韩国栗蜜(KCH)具有多种药理活性,如抗氧化、抗菌和抗炎作用;然而,其对HSV-1的抗病毒作用尚未见报道。因此,我们在细胞水平上确定了HSV-1感染后KCH的抗病毒活性及其作用机制。KCH通过结合和杀病毒步骤抑制宿主细胞的HSV-1感染。KCH降低了HSV-1感染后活性氧(ROS)和钙(Ca)的产生,并通过抑制活化B细胞核因子κB(NF-κB)活性来抑制炎性细胞因子的产生。此外,我们发现KCH在HSV-1感染期间抑制了NOD样受体蛋白3(NLRP3)炎性小体的表达。综上所述,KCH的抗病毒作用通过多个靶点发挥,包括抑制病毒复制和ROS介导的NLRP3炎性小体途径。我们的研究结果表明,KCH在治疗HSV-1感染及相关疾病方面具有潜力。